DLA PIPER LLP (US)

Lobbying for AVALYN PHARMA INC. · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Jul 17, 2026

Lobbying activity 2

Medical/Disease Research/Clinical Labs

Issues related to lung disease and rare disease.

Health Issues

Issues related to lung disease and rare disease.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.